Briefings

What is changing in the rules, what it means for your product, your municipality or your project, and who here handles it. In English and Portuguese.

Monitoring reports, cosmetic products

Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.

210 items

Results

Monitoring report

SCCS Preliminary Opinion on the inhalation toxicity of Acetylated Vetiver Oil in sprayable cosmetic products

Ingredients: ACETYLATED VEVITER OIL

Date of publication: 28/02/2024

On February 28 2024, the Scientific Committee on Consumer Safety (SCCS) published a preliminary Opinion on the inhalation toxicity of the fragrance ingredient Acetylated Vetiver Oil (AVO, CAS No 84082-84-8, EC No 282-031-1) in sprayable cosmetic products. The deadline for comments is set to May 3, 2024.

Monitoring report

European Union notifies WTO of the draft 22nd ATP to CLP Regulation – Impact in cosmetics

Topic: Draft 22nd ATP to CLP Regulation

Date of publication: 18/01/2024

On January 18, 2024, the European Commission (EC) notified the World Trade Organization's (WTO) Technical Barriers to Trade (TBT) Committee about the 22nd Adaptation to Technical and Scientific Progress (ATP) to Regulation (EC) 1272/2008, also known as CLP Regulation. This update amends 42 substances or substance groups and deletes one entry.

Monitoring report

General Product Safety Regulation requirements for cosmetics sold online 

Topic: REQUIREMENTS FOR COSMETICS SOLD ONLINE – GPSR – REGULATION 2023/988

Date of publication: 23/05/2023

Article 19 of the GPSR Regulation 2023/988 stipulates the requirements that must be fulfilled by the economic operators to be able to sell cosmetics online.

Monitoring report

SCCS issues Final Opinion on Methylparaben

Ingredients: METHYLPARABEN

Date of publication: 14/12/2023

On December 14 2023, the Scientific Committee on Consumer Safety (SCCS) published the Final Opinion on Methylparaben.

Monitoring report

SCCS issues Final Opinion on Silver Zinc Zeolite

Ingredients: ALUMINIUM

Date of publication: 14/12/2023

On December 14 2023, the Scientific Committee on Consumer Safety (SCCS) published the Preliminay Opinion on the use of aluminium in cosmetic products. The deadline for comments is set to February 16, 2024.

Monitoring report

SCCS Preliminary Opinion on Benzophenone-4

Ingredients: BENZOPHENONE-4

Date of publication: 14/12/2023

On December 14 2023, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the use of Benzophenone-4 in cosmetic products. The deadline for comments is set to February 16, 2024.

Cosmetic Products

Monitoring report

European Commission requests SCCS Opinion on the safety of Cyclamen Aldehyde

Ingredient: CYCLAMEN ALDEHYDE

Date of publication: 8 June 2026

The Scientific Committee on Consumer Safety (SCCS) has accepted a mandate to assess the safety of Cyclamen Aldehyde, following potential classification as a reproductive toxicant under the CLP Regulation.

Monitoring report

European Cosmetics Regulation – Updates on Cosmetic Ingredients  

Topic: NEW RESTRICTIONS ON COSMETIC INGREDIENTS

Date of publication: 13 January 2026

The European Commission published Commission Regulation (EU) 2026/78, which brings new restrictions on several cosmetic ingredients that were classified as Carcinogenic, Mutagenic or Toxic for Reproduction (CMR).

Monitoring report

United Kingdom publishes Technical Report on the Classification and Labelling of Talc 

Ingredient: TALC

Date of publication: January 2026

The United Kingdom (UK) Health and Safety Executive (HSE) has published a technical report concluding that Talc does not warrant carcinogenicity classification, diverging from ECHA's Risk Assessment Committee (RAC) opinion supporting Category 1B classification.

Medical Devices

EU

How to demonstrate equivalence under the MDR

Clinical data from an equivalent device can support your clinical evaluation, but the MDR sets a higher bar than the Directives did. The three characteristics, data access, and documentation.

Follow an area

One email when an area publishes, in the language you choose. Nothing else.